Lupin Expands Its Global Specialty Ophthalmology through Acquisition of VISUfarma

Lupin Strengthens Its Global Specialty Ophthalmology Business

Lupin Limited, a prominent global pharmaceutical company headquartered in India, has taken a significant step to enhance its presence in the ophthalmology sector by acquiring VISUfarma B.V. from GHO Capital Partners LLP. This major acquisition was officially announced on September 29, 2025, and it aligns with Lupin's strategy of expanding its business footprint in Europe and bolstering its global specialty franchise.

VISUfarma, established in 2016 through the merger of Visufarma SpA and the European commercial activities of Nicox SA, specializes in ophthalmology. The company generated revenue of €48 million in 2024 across several key markets, including Italy, the UK, Spain, Germany, and France. With a portfolio of over 60 innovative eye care products, VISUfarma has established itself as a notable player in the European healthcare landscape.

The acquisition of VISUfarma allows Lupin to integrate a fully operational business with a comprehensive range of eye health products including those for dry eyes, glaucoma, blepharitis, retinal health, and nutraceuticals. As the global demographic ages and the prevalence of diabetes-related eye complications increases, the need for innovative ophthalmic solutions continues to grow, making this acquisition timely and strategic.

Vinita Gupta, Lupin's CEO, expressed her enthusiasm about the acquisition, stating, "We are thrilled to welcome VISUfarma to the Lupin family. This acquisition reaffirms our commitment to providing innovative medications to the patients and communities we serve. Beyond its immediate impact, it also extends our reach in Europe and strengthens our specialized ophthalmology franchise."

By incorporating VISUfarma's established infrastructure and commercial operations, Lupin stands poised to capture the opportunities presented within the booming global ophthalmology market. The firm's consolidated European operations offer enhanced market expansion and diversification, paving the way for increased growth opportunities in key European countries.

The financial aspects of the acquisition were covered using Lupin's existing cash reserves, with the transaction expected to close by the end of 2025, pending certain closing conditions. This strategic move is anticipated to enhance Lupin’s growth trajectory and profitability margins.

GHO Capital’s involvement has been pivotal in transforming VISUfarma into a pan-European entity with a solid operational foundation in key markets. Their support has empowered VISUfarma to grow and effectively deliver services that cater to significant medical needs within the ophthalmologic sector. Andrea Ponti and Mike Turner from GHO Capital emphasize the successful collaboration that has led to a robust partnership aimed at driving VISUfarma’s future growth.

In conclusion, the integration of VISUfarma not only complements Lupin’s existing offerings but also underscores its commitment to innovation in ophthalmic care, ultimately aiming to improve the health outcomes of patients throughout Europe. As the company embarks on this new chapter, the potential for enhanced market penetration across the continent looms large, setting up a promising future for Lupin and its stakeholders.

For more information about Lupin and its products, visit www.lupin.com or follow them on LinkedIn.